Poor responses to tyrosine kinase inhibitors in a child with precursor B‐cell acute lymphoblastic leukemia with SNX2‐ABL1 chimeric transcript. (28th November 2013)

• Record Type: Journal Article
• Authors: Masuzawa, Aki; Kiyotani, Chikako; Osumi, Tomoo; Shioda, Yoko; Iijima, Kazutoshi; Tomita, Osamu; Nakabayashi, Kazuhiko; Oboki, Keisuke; Yasuda, Kazuki; Sakamoto, Hiromi; Ichikawa, Hitoshi; Hata, Kenichiro; Yoshida, Teruhiko; Matsumoto, Kenji; Kiyokawa, Nobutaka; Mori, Tetsuya
• Is Part Of: European journal of haematology. Volume 92:Number 3(2014:Mar.)
• Page Start: 263
• Page End: 267
• Publication Date: 2013-11-28
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12234
• Languages: English
• ISSNs: 0902-4441

Abstract

<abstract abstract-type="main" id="ejh12234-abs-0001"> <title>Abstract</title> <p>In addition to <italic>BCR</italic>, various rare fusion partners for the <italic>ABL1</italic> gene have been reported in leukemia. We have identified the fusion gene <italic>SNX2‐ABL1</italic> in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a <italic>SNX2‐ABL1</italic> fusion exhibited a <italic>BCR‐ABL1</italic>+ ALL‐like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype‐based treatment stratification for patients with <italic>SNX2‐ABL1</italic> fusion.</p> </abstract>